Why Is CRISPR Genome-Editing Firm Caribou Biosciences Stock Trading Higher Today>

Benzinga11-04

Caribou Biosciences Inc. (NASDAQ:CRBU) stock surged on Monday. The company said the CAR-T therapy induced complete and durable remissions in patients with advanced B-cell lymphoma. The CRISPR genome-...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2580924345?lang=en_US&edition=fundamental","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/11/03/Gene-editing.jpeg?optimize=medium&dpr=2&auto=webp&width=630","is_english":true,"pubTime":"2025-11-04 00:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2580924345","market":"nz","top_or_hot":-1,"title":"Why Is CRISPR Genome-Editing Firm Caribou Biosciences Stock Trading Higher Today>","media":"Benzinga","content":"<div>\n<p>Caribou Biosciences Inc. (NASDAQ:CRBU) stock surged on Monday. The company said the CAR-T therapy induced complete and durable remissions in patients with advanced B-cell lymphoma.\nThe CRISPR genome-...</p>\n\n<a href=\"https://www.benzinga.com/news/fda/25/11/48596655/why-is-crispr-genome-editing-firm-caribou-biosciences-stock-trading-higher-today\">Source Link</a>\n\n</div>\n","source":"benzinga_hot_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Is CRISPR Genome-Editing Firm Caribou Biosciences Stock Trading Higher Today></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Is CRISPR Genome-Editing Firm Caribou Biosciences Stock Trading Higher Today>\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-11-04 00:48 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/news/fda/25/11/48596655/why-is-crispr-genome-editing-firm-caribou-biosciences-stock-trading-higher-today><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Caribou Biosciences Inc. (NASDAQ:CRBU) stock surged on Monday. The company said the CAR-T therapy induced complete and durable remissions in patients with advanced B-cell lymphoma.\nThe CRISPR genome-...</p>\n\n<a href=\"https://www.benzinga.com/news/fda/25/11/48596655/why-is-crispr-genome-editing-firm-caribou-biosciences-stock-trading-higher-today\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CAR","symbol_name":"安飞士","start_time":0,"source_url":"https://www.benzinga.com/news/fda/25/11/48596655/why-is-crispr-genome-editing-firm-caribou-biosciences-stock-trading-higher-today","article_id":"2580924345","we_media_id":null,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/11/03/Gene-editing.jpeg?optimize=medium&dpr=2&auto=webp&width=630"],"rights":{"source":"benzinga_hot_news","url":"https://www.benzinga.com/news/fda/25/11/48596655/why-is-crispr-genome-editing-firm-caribou-biosciences-stock-trading-higher-today","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2580924345","pubTimestamp":1762188480,"columns":[],"sourceInfo":{"source_id":"benzinga_hot_news","name":"Benzinga"},"weMediaInfo":null,"summary":"Caribou Biosciences Inc.  stock surged on Monday. The company said the CAR-T therapy induced complete and durable remissions in patients with advanced B-cell lymphoma.The CRISPR genome-editing biopharmaceutical company shared preliminary results from its ongoing ANTLER phase 1 trial of vispacabtagene regedleucel , an allogeneic anti-CD19 CAR-T cell therapy, for relapsed or refractory B-cell non-Hodgkin lymphoma.The cell therapy uses T-cells from a healthy donor, rather than the patient's own cells, to fight cancer.Also Read: FDA Halts Trials Exporting Americans' Cells To Hostile Countries For Genetic Engineering. In the study, 64% of patients treated with Caribou's therapy achieved a complete response. The overall response rate was 82%.In recent interactions, the FDA has recommended that the company conduct a randomized, controlled trial in second-line  large B-cell lymphoma  CD19-naive patients who are ineligible for transplant and autologous CAR-T cell therapy.The company is advancin","collect":0,"end_time":0,"defaultTopTitle":"benzinga.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"CAR":"安飞士","BK4022":"陆运","BK4588":"碎股","CRBU":"Caribou Biosciences","BK4539":"次新股","BK4230":"旅客陆运","BK4556":"基因编辑","BK4585":"ETF&股票定投概念","LU1861559042.SGD":"日兴方舟颠覆性创新基金B SGD","LU1861558580.USD":"日兴方舟颠覆性创新基金B","BK4611":"AI医疗","BK4139":"生物科技","CRSP":"CRISPR Therapeutics AG"},"translate_title":"为什么CRISPR基因组编辑公司Caribou Biosciences股票今天交易走高>","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CRSP":1.5,"CAR":0.63,"CRBU":1.5},"content_text":"Caribou Biosciences Inc. (NASDAQ:CRBU) stock surged on Monday. The company said the CAR-T therapy induced complete and durable remissions in patients with advanced B-cell lymphoma.\nThe CRISPR genome-editing biopharmaceutical company shared preliminary results from its ongoing ANTLER phase 1 trial of vispacabtagene regedleucel (vispa-cel; formerly CB-010), an allogeneic anti-CD19 CAR-T cell therapy, for relapsed or refractory B-cell non-Hodgkin lymphoma.\nThe cell therapy uses T-cells from a healthy donor, rather than the patient's own cells, to fight cancer.\nAlso Read: FDA Halts Trials Exporting Americans' Cells To Hostile Countries For Genetic Engineering\nIn the study, 64% of patients treated with Caribou's therapy achieved a complete response. The overall response rate was 82%.\nAt one year, progression-free survival was 51% (patients remain alive without their cancer worsening).\nCaribou said data from this 35-patient cohort further confirmed that the efficacy and durability of vispa-cel are on par with the autologous CAR-T cell therapies.\nIn all patients treated in ANTLER (N=84), vispa-cel has demonstrated a generally well-tolerated safety profile.\nIn recent interactions, the FDA has recommended that the company conduct a randomized, controlled trial in second-line (2L) large B-cell lymphoma (LBCL) CD19-naive patients who are ineligible for transplant and autologous CAR-T cell therapy.\nThe company intends to follow this approach with its planned pivotal phase 3 trial design, evaluating approximately 250 patients.\nSeparately, Caribou shared the first clinical data from the dose escalation phase of the ongoing CaMMouflage Phase 1 trial of CB-011, an off-the-shelf anti-BCMA CAR-T cell therapy, in patients with relapsed or refractory multiple myeloma.\nThe company is advancing the program into dose expansion, which it expects to initiate by the end of this year, and it plans to share dose expansion data in 2026.\nOverall response rate was 92%, and complete response rate was 75%. 91% of the patients achieved minimal residual disease (MRD) negativity (no cancer cells were detected).\nCB-011 had a manageable safety profile across all dose levels and lymphodepletion regimens (N=48).\nPrice Action: CRBU stock is up 17.56% at $2.84 at the last check on Monday.\nRead Next:\nPhoto via Shutterstock","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2580924345","isCrawlerRequest":true}